论文部分内容阅读
JAK2V617F基因突变检测刷新了骨髓增殖性疾病的诊断标准,使更多原发性血小板增多症(ET)患者得到及时诊断。但是对未发生JAK2V617F基因突变的血小板增多患者,诊断ET时应特别慎重,需严格排除反应性血小板增多的原因。笔者经治1例患者,多家三级医院均诊断ET,行阿司匹林抗血小板治疗后出现消化道大出血,经消化道内镜检查明确为消化性溃疡伴出血致反应
The JAK2V617F gene mutation test has refreshed the diagnostic criteria for myeloproliferative disease, enabling more patients with essential thrombocythemia (ET) to be diagnosed promptly. However, patients with thrombocytosis who do not have a mutation in the JAK2V617F gene should be particularly careful when diagnosing ET and the exact cause of reactive thrombocytopenia should be strictly excluded. The author of a patient by the rule, a number of tertiary hospitals were diagnosed ET, aspirin line antiplatelet treatment of gastrointestinal bleeding, the gastrointestinal endoscopy clear peptic ulcer with bleeding reaction